36 studies found for:    " September 08, 2010":" October 08, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 08, 2010":" October 08, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients
Condition: HIV Positive Patient Receive Implant Supported Restoration
2 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
3 Completed
Has Results
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Etravirine;   Drug: Ritonavir;   Drug: Darunavir
4 Completed A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
5 Recruiting The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Conditions: Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
6 Completed Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
7 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Etravirine
8 Recruiting Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
9 Recruiting Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
10 Recruiting The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
Condition: HIV
Intervention: Procedure: Lymph node biopsy
11 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
12 Unknown  R5 Integrase Study in HIV-1 Naive Patients
Condition: HIV Infections
Intervention: Drug: Raltegravir and Maraviroc in combination
13 Unknown  Measurement of Plasma and Intracellular Concentrations of Raltegravir
Condition: HIV
Intervention: Drug: Raltegravir
14 Recruiting Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Condition: HIV
15 Recruiting Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort
Conditions: HIV;   AIDS
16 Completed HIV-1 Resistance at Screening for HIV Prevention Studies
Condition: HIV
Interventions: Procedure: Laboratory Testing;   Other: Counseling/referral
17 Completed Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
Conditions: HIV Infection;   Tuberculosis;   Immunosuppression
18 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
19 Completed Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
20 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years